 Vivos Therapeutics NASDAQ: VVOS is surging higher today after the company announced the U.S. Food and Drug Administration granted 510k market clearance to its mmRNA device for treating mild to moderate OSA, sleep-disordered breathing and snoring in adults. The FDA clearance paves the way for expanded insurance reimbursement coverage for the mmRNA device. 